Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis ; volume:35 ; number:8 ; day:16 ; month:7 ; year:2021 ; pages:805-820 ; date:8.2021
CNS drugs ; 35, Heft 8 (16.7.2021), 805-820, 8.2021
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-021-00834-9
- URN
-
urn:nbn:de:101:1-2021103121281678464859
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:29:42+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Overeem, Lucas Hendrik
- Raffaelli, Bianca
- Mecklenburg, Jasper
- Kelderman, Tim
- Neeb, Lars
- Reuter, Uwe
- SpringerLink (Online service)
Other Objects (12)
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Episodic Migraine and Older Adults
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Episodic Migraine and Older Adults
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis